OCUL Quote, Financials, Valuation and Earnings

iBio has a net margin of -236.58% compared to Ocular Therapeutix's net margin of -4444.57%. Ocular Therapeutix's return on equity of -70.49% beat iBio's return on equity of -148.3%.

Ocular Therapeutix has a consensus price target of $18.22, signalling upside risk potential of 127.49%. On the other hand iBio has an analysts' consensus of $3.60 which suggests that it could grow by 27.21%. Given that Ocular Therapeutix has higher upside potential than iBio, analysts believe Ocular Therapeutix is more attractive than iBio.

Ocular Therapeutix has a beta of 1.232, which suggesting that the stock is 23.238% more volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $15.4M, which are larger than iBio quarterly revenues of $175K. Ocular Therapeutix's net income of -$36.5M is lower than iBio's net income of -$4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 18.09x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -236.58% compared to Ocular Therapeutix's net margin of -49.65%. Ocular Therapeutix's return on equity of -70.49% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ocular Therapeutix has a consensus price target of $18.22, signalling upside risk potential of 127.49%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 408.46%. Given that NovaBay Pharmaceuticals has higher upside potential than Ocular Therapeutix, analysts believe NovaBay Pharmaceuticals is more attractive than Ocular Therapeutix.

Ocular Therapeutix has a beta of 1.232, which suggesting that the stock is 23.238% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $15.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ocular Therapeutix's net income of -$36.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 18.09x versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -236.58% compared to Ocular Therapeutix's net margin of -2357.27%. Ocular Therapeutix's return on equity of -70.49% beat Palatin Technologies's return on equity of --.

Ocular Therapeutix has a consensus price target of $18.22, signalling upside risk potential of 127.49%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1503.77%. Given that Palatin Technologies has higher upside potential than Ocular Therapeutix, analysts believe Palatin Technologies is more attractive than Ocular Therapeutix.

Ocular Therapeutix has a beta of 1.232, which suggesting that the stock is 23.238% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $15.4M, which are larger than Palatin Technologies quarterly revenues of $350K. Ocular Therapeutix's net income of -$36.5M is lower than Palatin Technologies's net income of -$7.8M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 18.09x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -236.58% compared to Ocular Therapeutix's net margin of --. Ocular Therapeutix's return on equity of -70.49% beat Theriva Biologics's return on equity of --.

Ocular Therapeutix has a consensus price target of $18.22, signalling upside risk potential of 127.49%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 6014.87%. Given that Theriva Biologics has higher upside potential than Ocular Therapeutix, analysts believe Theriva Biologics is more attractive than Ocular Therapeutix.

Ocular Therapeutix has a beta of 1.232, which suggesting that the stock is 23.238% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $15.4M, which are larger than Theriva Biologics quarterly revenues of --. Ocular Therapeutix's net income of -$36.5M is lower than Theriva Biologics's net income of -$7.7M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 18.09x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.